SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001213900-24-009767
Filing Date
2024-02-05
Accepted
2024-02-02 18:05:27
Documents
2

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13D ea192731-13da1hanmi_aptose.htm SC 13D/A 50494
2 SUBSCRIPTION AGREEMENT, DATED AS OF JANUARY 25, 2024, BY AND BETWEEN THE REPORTI ea192731ex99-1_aptose.htm EX-99.1 275993
  Complete submission text file 0001213900-24-009767.txt   328414
Mailing Address 251 CONSUMERS ROAD SUITE 1105 TORONTO A6 M2J 4R3
Business Address 251 CONSUMERS ROAD SUITE 1105 TORONTO A6 M2J 4R3 647-479-9828
Aptose Biosciences Inc. (Subject) CIK: 0000882361 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-49893 | Film No.: 24593185
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 14, WIRYESEONG-DAERO, SONGPA-GU SEOUL M5 05545
Business Address 14, WIRYESEONG-DAERO, SONGPA-GU SEOUL M5 05545 8224108796
Hanmi Pharmaceutical Co., Ltd. (Filed by) CIK: 0001904921 (see all company filings)

IRS No.: 000000000 | State of Incorp.: M5 | Fiscal Year End: 1231
Type: SC 13D/A